NeoGenomics, Inc. Stock News

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, and clinical trial operational optimization. CTO-H provides a research data solution that is unprecedented in its scale, longitudinality and biomarker depth. CTO-H is a major outcome of the collabo...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 (booth #830).

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Felicia Williams to its Board of Directors.

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.

NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Jeffrey Sherman - Chief Financial Officer Warren Stone - Chief Commercial Officer Kareem Saad - Head, Strategy and Transformation Andrew Lukowiak - Chief Innovation Officer Nate Montgom...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has received conditional approval from the NYSDOH for its Neo Comprehensive Solid Tumor assay and NeoTYPE DNA & RNA Lung test.